Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Summary

This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain cells.

Timeline

Start

2017-05-17

Primary completion

2019-05-29

Completion

2019-05-29

Outcome

Outcome not reported

Stopped: “due to poor response”

Publications

• Bennani NN, Kim HJ, Pederson LD, Atherton PJ, Micallef IN, Thanarajasingam G, Nowakowski GS, Witzig T, Feldman AL, Ansell SM. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. J Immunother Cancer. 2022 Jun;10(6):e004984. doi: 10.1136/jitc-2022-004984.

Drugs

Indications